



# Navigenics Translational Partnerships



## **Primary Objectives:**

- 1) Understand what hopes or expectations do patients have regarding the significance of predictive genetic testing?
  - a) Determine whether patients understand the limitations and benefits of genetic risk assessment
- 2) Understand how, if at all, genetic risk data impacts information provided by family medical histories
- 3) Compare three strategies: 1) DTC, 2) DTC with Genetic Counselor follow-up and Direct to Mayo Physician of delivering genetic risk assessment information.

## **Secondary Objectives:**

- 1) Assess Physicians expectation, understanding of limitations and benefits, and impact—if any—on decision-making in outpatient health screening environment

## **Future Objectives:**

- 1) Collect preliminary data that will inform the development of a larger clinical trial and provide data for an application for Federal funding

## **Primary Objective:**

To assess the capability of Cleveland Clinic's Genomic Medicine Institute's hereditary cancer risk assessment independently and together with Navigenics' whole genome SNP analysis to detect individuals at high risk for monogenic cancer syndromes including breast, colon, and prostate cancers.

**Participants:** 25 pairs; one member of the pair must have a personal history of breast, colon, and/or prostate cancer

A minimum of 10 individuals with a personal history of breast cancer will be recruited. Five of these individuals will have a clinically confirmed gene mutation (BRCA1/2, PTEN, p53, CDH1, or STK11). A minimum of 10 individuals with a personal history of colon cancer will be recruited. Five of these individuals will have a clinically confirmed gene mutation (MLH1, MSH2, MSH6, APC, MYH, BMPR1A, or SMAD4) A minimum of 5 individuals with a personal history of prostate cancer will be recruited

**Primary Objective:**

To understand if participating in consumer genomic testing will improve health by motivating people to make positive changes in their lifestyle (such as exercising and quitting smoking) and improve health outcomes by influencing conditions that are inherited.

**Co-sponsors:**


Navigenics Inc. Affymetrix, Inc. and Microsoft Corp.

**Participants:**

10,000 individuals, aged 18 and up


1

### Sample Acquisition + Analysis



2

### Confidential Results



3

### Stored in Health Vault



4

### Ongoing Surveys And Updates



5

### Genomic Data Stored at TSRI



The NEW ENGLAND JOURNAL of MEDICINE

nature genetics

